MiNK Therapeutics Statistics
Want to see INKT full AI Analyst Report?
MiNK Therapeutics (INKT) Stock Statistics & Valuation Metrics
Total Valuation
MiNK Therapeutics has a market cap or net worth of $47.95M. The enterprise value is $56.57M.
- Market Cap
- $47.95M
- Enterprise Value
- $56.57M
Share Statistics
MiNK Therapeutics has 5,133,645 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 5,133,645
- Owned by Insiders
- 4.95%
- Owned by Institutions
- 4.52%
Financial Efficiency
MiNK Therapeutics’s return on equity (ROE) is 0.88 and return on invested capital (ROIC) is -195.52%.
- Return on Equity (ROE)
- 0.88
- Return on Assets (ROA)
- -0.88
- Return on Invested Capital (ROIC)
- -195.52%
- Return on Capital Employed (ROCE)
- -10.34
- Revenue Per Employee
- 0
- Profits Per Employee
- -832.95K
- Employee Count
- 15
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of MiNK Therapeutics is -4.17. MiNK Therapeutics’s PEG ratio is -0.13.
- PE Ratio
- -4.17
- PS Ratio
- 238.31
- PB Ratio
- 0.00
- Price to FCF
- -0.01
- Price to Operating Cash Flow
- -0.01
- PEG Ratio
- -0.13
Income Statement
In the last 12 months, MiNK Therapeutics had revenue of 0 and earned -12.49M in profits. Earnings per share was -2.93.
- Revenue
- 0
- Gross Profit
- -181.75K
- Operating Income
- -12.49M
- Pretax Income
- -12.49M
- Net Income
- -12.49M
- EBITDA
- -12.31M
- Earnings Per Share (EPS)
- -2.93
Cash Flow
In the last 12 months, operating cash flow was -5.09B and capital expenditures -3, giving a free cash flow of -5.09B billion.
- Operating Cash Flow
- -5.09B
- Free Cash Flow
- -5.09B
- Free Cash Flow per Share
- -998.13
Dividends & Yields
MiNK Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -10685.88%
- Earnings Yield
- -23.13%
Stock Price Statistics
- Beta
- 0.09
- 52-Week Price Change
- -29.35%
- 50-Day Moving Average
- 11.14
- 200-Day Moving Average
- 11.19
- Relative Strength Index (RSI)
- 36.27
- Average Volume (3m)
- 14.72K
Important Dates
MiNK Therapeutics upcoming earnings date is Mar 23, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 11, 2026
- Next Earnings Date
- Mar 23, 2027
- Ex-Dividend Date
- ―
Financial Position
MiNK Therapeutics as a current ratio of 1.06, with Debt / Equity ratio of -36.40%
- Current Ratio
- 1.06
- Quick Ratio
- 1.06
- Debt to Market Cap
- 0.11
- Net Debt to EBITDA
- 0.66
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, MiNK Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
MiNK Therapeutics EV to EBITDA ratio is -3.45, with an EV/FCF ratio of -0.01.
- EV to Sales
- 200.96
- EV to EBITDA
- -3.45
- EV to Free Cash Flow
- -0.01
- EV to Operating Cash Flow
- -0.01
Balance Sheet
MiNK Therapeutics has $7.47M in cash and marketable securities with $0.00 in debt, giving a net cash position of $7.47M billion.
- Cash & Marketable Securities
- $7.47M
- Total Debt
- $0.00
- Net Cash
- $7.47M
- Net Cash Per Share
- $1.46
- Tangible Book Value Per Share
- -$3.18
Margins
Gross margin is -1373.98%, with operating margin of -6006.25%, and net profit margin of -5512.48%.
- Gross Margin
- -1373.98%
- Operating Margin
- -6006.25%
- Pretax Margin
- -5512.48%
- Net Profit Margin
- -5512.48%
- EBITDA Margin
- -5820.17%
- EBIT Margin
- -5901.46%
Analyst Forecast
The average price target for MiNK Therapeutics is $44.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $44.00
- Price Target Upside
- 371.09% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 25.94%
Scores
- Smart Score
- 9
- AI Score
- 47
